Research progress of intravitreal Dexamethasone implant in the treatment of non-infectious uveitic macular edema
10.3980/j.issn.1672-5123.2020.2.14
- VernacularTitle:地塞米松玻璃体内植入剂治疗非感染性葡萄膜炎继发黄斑水肿的研究进展
- Author:
Xiao-Guang Zhang
1
,
2
,
3
Author Information
1. 1Inner Mongolia Chaoju Eye Hospital, Hohhot 010050, Inner Mongolia Autonomous Region, China
2. 2Dalad Banner Chaoju Eye Hospital, Ordos 014300, Inner Mongolia Autonomous Region, China
3. 3Department of Ophthalmology, the First Hospital of China Medical University, Shenyang 110001, Liaoning Province, ChinaCo-first authors: Xiao-Guang Zhang and Ji-Jun Yang.
- Publication Type:Journal Article
- Keywords:
intravitreal injection;
intravitreal dexamethasone implant;
non-infectious uveitis;
macular edema;
research progress
- From:
International Eye Science
2020;20(2):258-262
- CountryChina
- Language:Chinese
-
Abstract:
Macular edema(ME)is a typical non-specific complication of uveitis, one of the common causes of visual impairment in patients with non-infectious uveitis(NIU). The treatment of uveitis related ME is still challenging in clinic. Various agents, such as corticosteroids, anti-vascular endothelial growth factors, and immune-modulators, have been used for combating uveitis related ME. However, there is not enough evidence to support the efficacy of any of these agents. Intravitreal dexamethasone implant(IDI, Ozurdex©; Allergan Inc, Irvine, CA)is a widely administered corticosteroid for the long-term management of uveitic ME in certain cases. Recent studies have demonstrated that IDI effectively improves uveitis related ME, and this effect could be sustained for at least six months with close monitoring and retreatment, as needed. Currently, we reviewed major clinical studies about IDI in eyes with NIU and briefly overviewed their results.
- Full text:202002014.PDF
